UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 30, 2006
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts | 0-17999 | 04-2726691 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 995-2500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 - OTHER EVENTS
On August 31, 2006, ImmunoGen, Inc. (Nasdaq: IMGN) announced that on August 30, 2006 sanofi-aventis U.S. LLC exercised its final contractual right to extend the term of its research collaboration with ImmunoGen for an additional year. Under the terms of the research collaboration, ImmunoGen will be entitled to $10.4 million of committed research support funding from sanofi-aventis over the twelve month period beginning September 1, 2007. Further, beginning September 1, 2006, ImmunoGen will no longer be obligated to present new targets for antibody-based anticancer therapeutics to sanofi-aventis enabling ImmunoGen to use such new targets in its development of proprietary products.
A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
Exhibit No. | Exhibit | |
99.1 | Press release of ImmunoGen, Inc. dated August 31, 2006 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ImmunoGen, Inc. | |||
(Registrant) | |||
Date: September 5, 2006 | /s/ Daniel M. Junius | ||
Daniel M. Junius | |||
Executive Vice President and Chief Financial Officer | |||
3
EXHIBIT INDEX
Exhibit No. | Exhibit | |
99.1 | Press release of ImmunoGen, Inc. dated August 31, 2006 |
4